News &amp; Updates

Low-dose colchicine reduced the risk of multiple cardiovascular (CV) outcomes in patients with chronic coronary disease, according to the LoDoCo2* trial presented at ESC 2020.

Old drug, new tricks: Colchicine for chronic coronary disease

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

Avacopan trumps steroids for ANCA-associated vasculitis

Avacopan, the oral inhibitor of complement activation, yields significant sustained remission compared with standard treatment with steroids in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), the ADVOCATE study shows.

Avacopan trumps steroids for ANCA-associated vasculitis

Single-dose nirsevimab prevents RSV-associated LRTI in preterm infants

A single-dose of nirsevimab helps prevent respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in preterm infants during an entire RSV season, according to a recent study.

Single-dose nirsevimab prevents RSV-associated LRTI in preterm infants

Nivolumab-ipilimumab displays potential in malignant pleural mesothelioma

24 Sep 2020 by

For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.

Nivolumab-ipilimumab displays potential in malignant pleural mesothelioma

Venetoclax-azacitidine duo may benefit older patients with AML

24 Sep 2020 by

The addition of venetoclax to azacitidine improved survival and remission rates in previously untreated adults with acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy (CT), the VIALE-A trial has shown.

Venetoclax-azacitidine duo may benefit older patients with AML

Glucocorticoid-associated weight gain not as bad as thought

The amount of weight gain associated with long-term exposure to glucocorticoids is lower than usually thought, according to a study.

Glucocorticoid-associated weight gain not as bad as thought

Selpercatinib shows promise in RET-mutant medullary thyroid cancer

Selective RET inhibition with selpercatinib has demonstrated durable efficacy with low-grade toxicity in medullary thyroid cancer patients harbouring RET mutation, according to the results of a phase I–II trial.

Selpercatinib shows promise in RET-mutant medullary thyroid cancer